Breaking News

Quay Pharma to Manufacture New Cancer Drug for Trial

October 27, 2016

Redx Pharma’s Porcupine inhibitor touted for potential to tackle hard-to-treat cancers

Contract development, manufacturing and packaging organization, Quay Pharma, has entered into an agreement with drug discovery and development company, Redx Pharma, to manufacture its new cancer treatment drug.

The new Porcupine inhibitor has the potential to tackle hard-to-treat cancers such as pancreatic, gastric and biliary. Quay will formulate the capsules, which will be administered during the drug’s first-in-human studies early 2017.

The new treatment will have the potential for patients to take it orally as a once-daily dose. The inhibitor targets an embryonic signaling pathway that assists maintaining cancer stem cells associated with tumorigenesis, metastasis, recurrence and resistance.

“We are delighted that Redx has selected Quay Pharma based upon our formulation development expertise, unparalleled flexibility and successful track record of delivering clinical trial supplies on time,” said Maireadh Pedersen, chief executive officer, Quay Pharma.

Neil Murray, chief executive officer, Redx Pharma, said, “Less than 10% of pancreatic cancer patients survive five years from their diagnosis. The potential for this new class of drugs to tackle some of these difficult cancers could see a significant advance for patients who have few meaningful treatment options today. Our Porcupine inhibitor is an especially exciting clinical candidate, both scientifically and commercially. We are pleased to confirm that we remain on track to enter the clinical trial phase early 2017.”
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research